Myriad Genetics Inc (MYGN) Stock Price, Quote & News - Mboum

Company Profile

Myriad Genetics, Inc., a molecular diagnostics and precision medicine company, develops molecular tests. The company offers molecular diagnostic tests for oncology, women's health, and pharmacogenomics. It also provides MyRisk Hereditary Cancer test, a DNA sequencing test for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic test, a DNA sequencing test for metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious...

Industry: Diagnostics & Research

Sector: Healthcare

Phone: 801 584 3600

Fax: 801 584 3640

Website: www.myriad.com

Address:

322 North 2200 West, Salt Lake City, United States

Fenerium_x Mar. 20 at 6:08 PM

$MYGN Myriads MyChoice CDx is now the only FDA-approved HRD test for guiding Zejula treatment in the U.S. Low public float, soon might go $REBN, $WNW

0 · Reply

The_Illuminati Mar. 20 at 1:46 PM

$MYGN Expecting a 5-7x here soon 👀

0 · Reply

Aliuse Mar. 19 at 5:52 PM

$MYGN https://www.marketbeat.com/instant-alerts/filing-fisher-asset-management-llc-purchases-219607-shares-of-myriad-genetics-inc-mygn-2025-12-05/

0 · Reply

Aliuse Mar. 19 at 5:52 PM

$MYGN https://www.zacks.com/stock/news/2885899/why-myriad-genetics-mygn-is-a-top-momentum-stock-for-the-long-term?cid=CS-STOCKTWITS-HL-tale_of_the_tape%7Czacks_education_momentum_score-2885899&adid=SYND_STOCKTWITS_HEADLINE_TALEOFTHETAPE_548_2885899

0 · Reply

Aliuse Mar. 19 at 5:27 PM

$MYGN volume is coming

0 · Reply

Aliuse Mar. 19 at 5:03 PM

$MYGN https://www.zacks.com/stock/news/2886575/why-myriad-genetics-mygn-is-a-top-growth-stock-for-the-long-term?cid=CS-STOCKTWITS-HL-tale_of_the_tape%7Czacks_education_growth_score-2886575&adid=SYND_STOCKTWITS_HEADLINE_TALEOFTHETAPE_547_2886575 Very bullish news

0 · Reply

Aliuse Mar. 18 at 7:14 PM

$MYGN be ready it’s on people’s radar

0 · Reply

Aliuse Mar. 18 at 5:29 PM

$MYGN https://www.zacks.com/stock/news/2883091/tempus-ai-expands-clinical-validation-of-ai-powered-cancer-diagnostics?cid=CS-STOCKTWITS-HL-analyst_blog%7Cquick_take-2883091&adid=SYND_STOCKTWITS_HEADLINE_ANALYSTBLOG_252_2883091 Partnership is coming soon it will cuz the stock to spike up

0 · Reply

Aliuse Mar. 18 at 5:28 PM

$MYGN https://www.zacks.com/stock/news/2885899/why-myriad-genetics-mygn-is-a-top-momentum-stock-for-the-long-term?cid=CS-STOCKTWITS-HL-tale_of_the_tape%7Czacks_education_momentum_score-2885899&adid=SYND_STOCKTWITS_HEADLINE_TALEOFTHETAPE_548_2885899

0 · Reply

bilocelhi Mar. 18 at 10:48 AM

$MYGN be careful here, could easily drop to high $3. Literally no interest currently in the pre PM

0 · Reply

Latest News on MYGN

Myriad Genetics Receives FDA Approval of the MyChoice CDx Test as the Companion Diagnostic for Zejula (niraparib) for Patients with Ovarian Cancer

Mar 17, 2026, 4:05 PM EDT - 4 days ago

Myriad Genetics Receives FDA Approval of the MyChoice CDx Test as the Companion Diagnostic for Zejula (niraparib) for Patients with Ovarian Cancer

Myriad Genetics Beats Q4 Expectations, Shares Surge Amid Core Franchise Growth

Feb 24, 2026, 10:10 AM EST - 25 days ago

Myriad Genetics Beats Q4 Expectations, Shares Surge Amid Core Franchise Growth

Myriad Genetics, Inc. (MYGN) Q4 2025 Earnings Call Transcript

Feb 23, 2026, 10:54 PM EST - 26 days ago

Myriad Genetics, Inc. (MYGN) Q4 2025 Earnings Call Transcript

Myriad Genetics Reports Fourth Quarter and Full-Year 2025 Financial Results; Reiterates 2026 Financial Guidance Reflecting Strengthened Execution

Feb 23, 2026, 4:05 PM EST - 26 days ago

Myriad Genetics Reports Fourth Quarter and Full-Year 2025 Financial Results; Reiterates 2026 Financial Guidance Reflecting Strengthened Execution

FirstGene Study Demonstrates High Analytical Sensitivity and Specificity for Each Component of the Test

Feb 19, 2026, 9:15 AM EST - 4 weeks ago

FirstGene Study Demonstrates High Analytical Sensitivity and Specificity for Each Component of the Test

Myriad Genetics to Release Fourth Quarter and Full Year 2025 Financial Results on February 23, 2026

Feb 16, 2026, 4:15 PM EST - 4 weeks ago

Myriad Genetics to Release Fourth Quarter and Full Year 2025 Financial Results on February 23, 2026

Myriad Genetics, Inc. (MYGN) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Jan 14, 2026, 11:05 PM EST - 2 months ago

Myriad Genetics, Inc. (MYGN) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Myriad Genetics Announces Select Preliminary Fourth Quarter and Full Year 2025 Financial Results and Introduces Full Year 2026 Financial Guidance

Jan 12, 2026, 8:30 AM EST - 2 months ago

Myriad Genetics Announces Select Preliminary Fourth Quarter and Full Year 2025 Financial Results and Introduces Full Year 2026 Financial Guidance

Myriad Genetics to Present at 44th Annual J.P. Morgan Healthcare Conference

Jan 5, 2026, 4:15 PM EST - 2 months ago

Myriad Genetics to Present at 44th Annual J.P. Morgan Healthcare Conference

Clairity, Myriad Genetics, and MagView Launch the First Integrated AI and Genetic Risk Platform for Personalized Breast Health

Nov 25, 2025, 4:15 PM EST - 4 months ago

Clairity, Myriad Genetics, and MagView Launch the First Integrated AI and Genetic Risk Platform for Personalized Breast Health

Myriad Genetics to Participate in Upcoming Investor Healthcare Conferences

Nov 11, 2025, 9:00 AM EST - 4 months ago

Myriad Genetics to Participate in Upcoming Investor Healthcare Conferences

Myriad Genetics: Downgrading To "Hold" Rating On Break-Even Q3 Earnings

Nov 5, 2025, 1:36 PM EST - 4 months ago

Myriad Genetics: Downgrading To "Hold" Rating On Break-Even Q3 Earnings

Myriad Genetics, Inc. (MYGN) Q3 2025 Earnings Call Transcript

Nov 3, 2025, 11:56 PM EST - 4 months ago

Myriad Genetics, Inc. (MYGN) Q3 2025 Earnings Call Transcript

Myriad Genetics Reports Third Quarter 2025 Financial Results; Reiterates 2025 Financial Guidance Following Continued Solid Execution

Nov 3, 2025, 4:05 PM EST - 4 months ago

Myriad Genetics Reports Third Quarter 2025 Financial Results; Reiterates 2025 Financial Guidance Following Continued Solid Execution

New Post-Hoc Analysis Shows Patients Whose Clinicians Had Access to GeneSight Results for Depression Treatment Are More Likely to Feel Better Sooner

Oct 31, 2025, 9:05 AM EDT - 5 months ago

New Post-Hoc Analysis Shows Patients Whose Clinicians Had Access to GeneSight Results for Depression Treatment Are More Likely to Feel Better Sooner

Myriad Genetics to Release Third Quarter 2025 Financial Results on November 3, 2025

Oct 27, 2025, 4:15 PM EDT - 5 months ago

Myriad Genetics to Release Third Quarter 2025 Financial Results on November 3, 2025

Myriad Genetics Adds F8, FXN Genes to Foresight Universal Plus Panel

Oct 14, 2025, 8:00 AM EDT - 5 months ago

Myriad Genetics Adds F8, FXN Genes to Foresight Universal Plus Panel

Breast Cancer Awareness Month: Patient and Clinician Share Insights on how to tackle the fear of cancer screenings on YourUpdateTV

Oct 8, 2025, 5:21 PM EDT - 5 months ago

Breast Cancer Awareness Month: Patient and Clinician Share Insights on how to tackle the fear of cancer screenings on YourUpdateTV

Myriad Genetics and SOPHiA GENETICS to Develop an Innovative Companion Diagnostic Offering in Liquid Biopsy

Sep 23, 2025, 8:01 AM EDT - 6 months ago

Myriad Genetics and SOPHiA GENETICS to Develop an Innovative Companion Diagnostic Offering in Liquid Biopsy

Myriad Genetics and SOPHiA GENETICS to Develop an Innovative Companion Diagnostic Offering in Liquid Biopsy

Sep 23, 2025, 8:00 AM EDT - 6 months ago

Myriad Genetics and SOPHiA GENETICS to Develop an Innovative Companion Diagnostic Offering in Liquid Biopsy

Myriad Genetics, Inc. (MYGN) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Sep 10, 2025, 11:06 AM EDT - 6 months ago

Myriad Genetics, Inc. (MYGN) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Myriad Genetics Announces Precise MRD Clinical Data Published in The Lancet Oncology

Sep 4, 2025, 7:00 PM EDT - 7 months ago

Myriad Genetics Announces Precise MRD Clinical Data Published in The Lancet Oncology

New Meta-Analysis Demonstrates that Access to the GeneSight Test Can Significantly Improve Response and Remission Rates for Patients with Depression

Sep 3, 2025, 4:30 PM EDT - 7 months ago

New Meta-Analysis Demonstrates that Access to the GeneSight Test Can Significantly Improve Response and Remission Rates for Patients with Depression

Myriad Genetics Appoints Ben Wheeler Chief Financial Officer

Aug 18, 2025, 8:30 AM EDT - 7 months ago

Myriad Genetics Appoints Ben Wheeler Chief Financial Officer

New Myriad Genetics Survey Uncovers Women Fear Screenings—But Feel Reassured by the Results

Aug 13, 2025, 8:00 AM EDT - 7 months ago

New Myriad Genetics Survey Uncovers Women Fear Screenings—But Feel Reassured by the Results

Myriad: HCT In Oncology Continues To Deliver Increased Volume And Revenue Growth

Aug 6, 2025, 5:51 PM EDT - 8 months ago

Myriad: HCT In Oncology Continues To Deliver Increased Volume And Revenue Growth

Myriad Genetics, Inc. (MYGN) Q2 2025 Earnings Call Transcript

Aug 6, 2025, 4:14 AM EDT - 8 months ago

Myriad Genetics, Inc. (MYGN) Q2 2025 Earnings Call Transcript

Myriad Genetics Reports Second Quarter 2025 Financial Results; Raises 2025 Revenue Guidance Following Positive Business Momentum

Aug 5, 2025, 4:05 PM EDT - 8 months ago

Myriad Genetics Reports Second Quarter 2025 Financial Results; Raises 2025 Revenue Guidance Following Positive Business Momentum

Myriad Genetics Announces Early Access to the FirstGene Multiple Prenatal Screen

Jun 3, 2025, 9:00 AM EDT - 10 months ago

Myriad Genetics Announces Early Access to the FirstGene Multiple Prenatal Screen

Myriad Genetics Highlights New Research Advancements and Oncology Innovations at 2025 ASCO Annual Meeting

May 27, 2025, 4:05 PM EDT - 10 months ago

Myriad Genetics Highlights New Research Advancements and Oncology Innovations at 2025 ASCO Annual Meeting

Bronstein, Gewirtz & Grossman, LLC Encourages Myriad Genetics, Inc. (MYGN) Shareholders to Inquire about Securities Investigation

May 27, 2025, 10:00 AM EDT - 10 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages Myriad Genetics, Inc. (MYGN) Shareholders to Inquire about Securities Investigation

Bronstein, Gewirtz & Grossman, LLC Is Investigating Myriad Genetics, Inc. (MYGN) And Encourages Shareholders to Connect

May 26, 2025, 10:00 AM EDT - 10 months ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Myriad Genetics, Inc. (MYGN) And Encourages Shareholders to Connect

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Myriad Genetics, Inc. (MYGN) And Encourages Shareholders to Reach Out

May 25, 2025, 10:00 AM EDT - 10 months ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Myriad Genetics, Inc. (MYGN) And Encourages Shareholders to Reach Out

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Myriad Genetics, Inc. (MYGN) and Encourages Shareholders to Learn More About the Investigation

May 23, 2025, 10:00 AM EDT - 10 months ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Myriad Genetics, Inc. (MYGN) and Encourages Shareholders to Learn More About the Investigation

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Myriad Genetics, Inc. (MYGN) and Encourages Investors to Learn More About the Investigation

May 22, 2025, 10:00 AM EDT - 10 months ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Myriad Genetics, Inc. (MYGN) and Encourages Investors to Learn More About the Investigation

Myriad Genetics, Inc. (MYGN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

May 21, 2025, 10:00 AM EDT - 10 months ago

Myriad Genetics, Inc. (MYGN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

Bronstein, Gewirtz & Grossman, LLC Is Investigating Myriad Genetics, Inc. (MYGN) And Encourages Investors to Connect

May 20, 2025, 10:00 AM EDT - 10 months ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Myriad Genetics, Inc. (MYGN) And Encourages Investors to Connect

Bronstein, Gewirtz & Grossman, LLC Encourages Myriad Genetics, Inc. (MYGN) Stockholders to Inquire about Securities Investigation

May 19, 2025, 10:00 AM EDT - 10 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages Myriad Genetics, Inc. (MYGN) Stockholders to Inquire about Securities Investigation

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Myriad Genetics, Inc. (MYGN) And Encourages Investors to Reach Out

May 16, 2025, 10:00 AM EDT - 11 months ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Myriad Genetics, Inc. (MYGN) And Encourages Investors to Reach Out

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Myriad Genetics, Inc. (MYGN) And Encourages Stockholders to Reach Out

May 15, 2025, 10:00 AM EDT - 11 months ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Myriad Genetics, Inc. (MYGN) And Encourages Stockholders to Reach Out

Updated: Myriad Genetics to Participate in Two Upcoming Investor Healthcare Conferences

May 14, 2025, 4:45 PM EDT - 11 months ago

Updated: Myriad Genetics to Participate in Two Upcoming Investor Healthcare Conferences

Fenerium_x Mar. 20 at 6:08 PM

$MYGN Myriads MyChoice CDx is now the only FDA-approved HRD test for guiding Zejula treatment in the U.S. Low public float, soon might go $REBN, $WNW

0 · Reply

The_Illuminati Mar. 20 at 1:46 PM

$MYGN Expecting a 5-7x here soon 👀

0 · Reply

Aliuse Mar. 19 at 5:52 PM

$MYGN https://www.marketbeat.com/instant-alerts/filing-fisher-asset-management-llc-purchases-219607-shares-of-myriad-genetics-inc-mygn-2025-12-05/

0 · Reply

Aliuse Mar. 19 at 5:52 PM

$MYGN https://www.zacks.com/stock/news/2885899/why-myriad-genetics-mygn-is-a-top-momentum-stock-for-the-long-term?cid=CS-STOCKTWITS-HL-tale_of_the_tape%7Czacks_education_momentum_score-2885899&adid=SYND_STOCKTWITS_HEADLINE_TALEOFTHETAPE_548_2885899

0 · Reply

Aliuse Mar. 19 at 5:27 PM

$MYGN volume is coming

0 · Reply

Aliuse Mar. 19 at 5:03 PM

$MYGN https://www.zacks.com/stock/news/2886575/why-myriad-genetics-mygn-is-a-top-growth-stock-for-the-long-term?cid=CS-STOCKTWITS-HL-tale_of_the_tape%7Czacks_education_growth_score-2886575&adid=SYND_STOCKTWITS_HEADLINE_TALEOFTHETAPE_547_2886575 Very bullish news

0 · Reply

Aliuse Mar. 18 at 7:14 PM

$MYGN be ready it’s on people’s radar

0 · Reply

Aliuse Mar. 18 at 5:29 PM

$MYGN https://www.zacks.com/stock/news/2883091/tempus-ai-expands-clinical-validation-of-ai-powered-cancer-diagnostics?cid=CS-STOCKTWITS-HL-analyst_blog%7Cquick_take-2883091&adid=SYND_STOCKTWITS_HEADLINE_ANALYSTBLOG_252_2883091 Partnership is coming soon it will cuz the stock to spike up

0 · Reply

Aliuse Mar. 18 at 5:28 PM

$MYGN https://www.zacks.com/stock/news/2885899/why-myriad-genetics-mygn-is-a-top-momentum-stock-for-the-long-term?cid=CS-STOCKTWITS-HL-tale_of_the_tape%7Czacks_education_momentum_score-2885899&adid=SYND_STOCKTWITS_HEADLINE_TALEOFTHETAPE_548_2885899

0 · Reply

bilocelhi Mar. 18 at 10:48 AM

$MYGN be careful here, could easily drop to high $3. Literally no interest currently in the pre PM

0 · Reply

Aliuse Mar. 18 at 8:37 AM

$MYGN https://www.marketbeat.com/instant-alerts/wells-fargo-company-cuts-myriad-genetics-nasdaqmygn-price-target-to-600-2026-02-24/

0 · Reply

Aliuse Mar. 18 at 8:36 AM

$MYGN https://www.marketbeat.com/instant-alerts/insider-buying-myriad-genetics-nasdaqmygn-director-acquires-6100-shares-of-stock-2026-02-27/

0 · Reply

Aliuse Mar. 18 at 8:36 AM

$MYGN https://www.marketbeat.com/instant-alerts/myriad-genetics-nasdaqmygn-director-s-louise-phanstiel-buys-48000-shares-2026-02-27/

0 · Reply

Aliuse Mar. 18 at 8:36 AM

$MYGN https://www.marketbeat.com/instant-alerts/myriad-genetics-inc-nasdaqmygn-given-consensus-recommendation-of-hold-by-brokerages-2026-03-02/

0 · Reply

Aliuse Mar. 18 at 8:36 AM

$MYGN https://www.marketbeat.com/instant-alerts/filing-royce-associates-lp-makes-new-484-million-investment-in-myriad-genetics-inc-mygn-2026-03-05/

0 · Reply

Aliuse Mar. 18 at 8:36 AM

$MYGN https://www.marketbeat.com/instant-alerts/myriad-genetics-nasdaqmygn-ceo-purchases-20000000-in-stock-2026-03-09/

0 · Reply

Aliuse Mar. 18 at 8:35 AM

$MYGN https://www.insidertrades.com/alerts/nasdaq-mygn-insider-buying-and-selling-2026-03-10/

0 · Reply

Aliuse Mar. 18 at 8:21 AM

$MYGN huge announcement it has not effected the price yet once volume increases it will go up

1 · Reply

Bulldozz Mar. 18 at 12:52 AM

$MYGN $TTD bullish.. got FDA approval

0 · Reply

J3_16 Mar. 17 at 10:12 PM

$MYGN $MYGN One of the smallest float pharmas that just got FDA approval. Float less than 1% of the total outstanding shares.

0 · Reply

J3_16 Mar. 17 at 9:59 PM

$MYGN Black rock added more at the end of February

0 · Reply

J3_16 Mar. 17 at 9:57 PM

$MYGN Insane insider activity.

0 · Reply